With oral VK2735 entering Phase 3 and injectable trials fully enrolled, Viking Therapeutics (NASDAQ: VKTX) is building a broader case in weight management.
Viking Therapeutics (NASDAQ: VKTX) has strengthened two foundations of its obesity-drug investment story: the capital to advance its programs…